Skip to main content

Advertisement

Table 2 Subject demographics and baseline characteristics, ITT population

From: Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder?

Characteristic, N = 164 Baseline Endpoint
Age, mean (SD), years 9.4 (1.9) -
Sex (%)   
Boys, n 117 (71.3) -
Girls, n 47 (28.7) -
Race, n (%)   
White 129 (78.7) -
African American 19 (11.6) -
Asian 1 (0.6) -
Native Hawaiian/ Other Pacific Islander 1 (0.6) -
American Indian/ Alaska Native 1 (0.6) -
Other 13 (7.9) -
Weight, mean (SD), lb 75.6 (26.0) -
Height, mean (SD), in 54.2 (5.2) -
ADHD-RS-IV Score (SD)   
Total 14.1 (7.5) 9.9 (7.5)
Inattentive 7.9 (4.3) 6.4 (5.3)
Hyperactive/impulsive 6.2 (4.5) 4.4 (4.5)
AIM-C Child Impact Score (SD)a 62.4 (20.5) 73.4 (18.4)
AIM-C Family Impact Score (SD)a 68.2 (23.3) 78.4 (21.7)
  1. aBased on 161 subjects
  2. ITT = intent to treat; ADHD-RS-IV = ADHD-Rating Scale-IV; AIM-C = ADHD Impact Module-Child